NCT01598987 arm group 20165bb9c02613f51033d77f52b4e309 [clinicaltrials_resource:NCT01598987/arm-group/20165bb9c02613f51033d77f52b4e309]
Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation. [clinicaltrials_resource:6ea285f335bcfebf91c6b43f2e358c5f]Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients. [clinicaltrials:NCT01598987]
arm group [clinicaltrials_vocabulary:arm-group]
NCT01598987 arm group 20165bb9c02613f51033d77f52b4e309 [clinicaltrials_resource:NCT01598987/arm-group/20165bb9c02613f51033d77f52b4e309]
Bio2RDF identifier
NCT01598987/arm-group/20165bb9c02613f51033d77f52b4e309
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 165bb9c02613f51033d77f52b4e309
description [clinicaltrials_vocabulary:description]
Conversion at Baseline from an ...... ine (CsA) or tacrolimus (TAC).
identifier
clinicaltrials_resource:NCT01598987/arm-group/20165bb9c02613f51033d77f52b4e309
title
NCT01598987 arm group 20165bb9c02613f51033d77f52b4e309
@en
type
label
NCT01598987 arm group 20165bb9 ...... 65bb9c02613f51033d77f52b4e309]
@en